Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 5 (May)

1. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
   Gastric Cancer, 8(2): 111-6. [Abstract] [Full-text]
2. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review.
   Gastric Cancer, 8(2): 95-102. [Abstract] [Full-text]
3. Recent advances in multimodal treatment for gastric cancer: a review.
   Gastric Cancer, 8(2): 78-85. [Abstract] [Full-text]
4. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
   Int J Clin Oncol, 10(2): 133-8. [Abstract] [Full-text]
5. Regulators of apoptosis: suitable targets for immune therapy of cancer.
   Nat Rev Drug Discov, 4(5): 399-409. [Abstract] [Full-text]
6. Rho kinase, a promising drug target for neurological disorders.
   Nat Rev Drug Discov, 4(5): 387-98. [Abstract] [Full-text]
7. The rise and rise of drug delivery.
   Nat Rev Drug Discov, 4(5): 381-5. [Abstract] [Full-text]
8. Self-reported medication use among adolescents in Kuwait.
   Med Princ Pract, 14(3): 161-4. [Abstract] [Full-text]
9. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
   Obstet Gynecol, 105(5): 1063-73. [Abstract] [Full-text]
10. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist.
    Obstet Gynecol, 105(5): 953-61. [Abstract] [Full-text]
11. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.
    Obstet Gynecol, 105(5): 944-52. [Abstract] [Full-text]
12. Hypodermoclysis--a victim of historical prejudice.
    Age Ageing, 34(3): 215-7. [Abstract] [Full-text]
13. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
    Lancet Oncol, 6(5): 287-94. [Abstract] [Full-text]
14. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Leuk Res, 29(6): 649-52. [Abstract] [Full-text]
15. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience.
    Leuk Res, 29(6): 609-15. [Abstract] [Full-text]
16. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
    Gynecol Oncol, 97(2): 710-2. [Abstract] [Full-text]
17. Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review.
    Gynecol Oncol, 97(2): 700-3. [Abstract] [Full-text]
18. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
    Gynecol Oncol, 97(2): 618-23. [Abstract] [Full-text]
19. Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.
    Gynecol Oncol, 97(2): 576-81. [Abstract] [Full-text]
20. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Gynecol Oncol, 97(2): 489-96. [Abstract] [Full-text]
21. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Gynecol Oncol, 97(2): 436-41. [Abstract] [Full-text]
22. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
    Gynecol Oncol, 97(2): 410-2. [Abstract] [Full-text]
23. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Eur J Cancer, 41(7): 998-1006. [Abstract] [Full-text]
24. A nationwide survey of physician office visits found that inappropriate antibiotic prescriptions were issued for bacterial respiratory tract infections in ambulatory patients.
    J Clin Epidemiol, 58(4): 414-20. [Abstract] [Full-text]
25. Clinical applications for targeted therapy in bladder cancer.
    Urol Clin North Am, 32(2): 239-46, vii. [Abstract] [Full-text]
26. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
    Urol Clin North Am, 32(2): 217-30, vii. [Abstract] [Full-text]
27. Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma.
    Pediatr Surg Int, 21(5): 364-8. [Abstract] [Full-text]
28. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Oncology, 68(1): 58-63. [Abstract] [Full-text]
29. Pexiganan-incorporated collagen matrices for infected wound-healing processes in rat.
    J Biomed Mater Res A, 73(3): 320-31. [Abstract] [Full-text]
30. Efficiency of magnetic liposomal transforming growth factor-beta 1 in the repair of articular cartilage defects in a rabbit model.
    J Biomed Mater Res A, 73(3): 255-63. [Abstract] [Full-text]
31. Immune responses in mice of beta-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres.
    J Biomed Mater Res A, 73(3): 332-8. [Abstract] [Full-text]
32. Therapeutic approaches to combating lipoatrophy: do they work?
    J Antimicrob Chemother, 55(5): 612-5. [Abstract] [Full-text]
33. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    J Antimicrob Chemother, 55(5): 800-4. [Abstract] [Full-text]
34. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Pediatr Blood Cancer, 44(7): 625-9. [Abstract] [Full-text]
35. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
    Oncology, 68(1): 2-9. [Abstract] [Full-text]
36. Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma.
    Pediatr Blood Cancer, 44(7): 679-81. [Abstract] [Full-text]
37. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis.
    Support Care Cancer, 13(5): 318-24. [Abstract] [Full-text]
38. Randomized comparison of intra-arterial and intravenous thrombolysis in a canine model of acute basilar artery thrombosis.
    Neuroradiology, 46(12): 988-95. [Abstract] [Full-text]
39. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res Treat, 91(1): 1-10. [Abstract] [Full-text]
40. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
    Invest New Drugs, 23(3): 263-9. [Abstract] [Full-text]
41. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
    Invest New Drugs, 23(3): 243-51. [Abstract] [Full-text]
42. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.
    Mem Inst Oswaldo Cruz, 100(1): 97-102. [Abstract] [Full-text]
43. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Mem Inst Oswaldo Cruz, 100(1): 73-8. [Abstract] [Full-text]
44. Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials.
    J Thorac Cardiovasc Surg, 129(5): 997-1005. [Abstract] [Full-text]
45. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    J Thorac Cardiovasc Surg, 129(5): 977-83. [Abstract] [Full-text]
46. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
    Cancer Res, 65(9): 3883-93. [Abstract] [Full-text]
47. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Cancer Res, 65(9): 3868-76. [Abstract] [Full-text]
48. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
    Cancer Res, 65(9): 3853-60. [Abstract] [Full-text]
49. Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies.
    Cancer Res, 65(9): 3823-7. [Abstract] [Full-text]
50. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
    Cancer Res, 65(9): 3716-25. [Abstract] [Full-text]
51. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Cancer Res, 65(9): 3707-15. [Abstract] [Full-text]
52. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.
    Cancer Res, 65(9): 3643-55. [Abstract] [Full-text]
53. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Clin Cancer Res, 11(9): 3417-24. [Abstract] [Full-text]
54. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
    Clin Cancer Res, 11(9): 3210-6. [Abstract] [Full-text]
55. Early-onset group B streptococcal disease in the era of maternal screening.
    Pediatrics, 115(5): 1240-6. [Abstract] [Full-text]
56. Treatment of varicocele: randomized prospective study on open surgery versus Tauber antegrade sclerotherapy.
    J Androl, 26(3): 328-32. [Abstract] [Full-text]
57. Plasma membrane poration induced by ultrasound exposure: implication for drug delivery.
    J Control Release, 104(1): 213-22. [Abstract] [Full-text]
58. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel.
    J Control Release, 104(1): 181-91. [Abstract] [Full-text]
59. Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part II: pharmacokinetics and biodistribution in normal and tumor-bearing rodents.
    J Control Release, 104(1): 155-66. [Abstract] [Full-text]
60. A novel enzymatic technique for limiting drug mobility in a hydrogel matrix.
    J Control Release, 104(1): 141-53. [Abstract] [Full-text]
61. Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part I: synthesis and characterization.
    J Control Release, 104(1): 129-39. [Abstract] [Full-text]
62. Novel sustained release microspheres for pulmonary drug delivery.
    J Control Release, 104(1): 79-90. [Abstract] [Full-text]
63. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu.
    J Control Release, 104(1): 67-77. [Abstract] [Full-text]
64. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery.
    J Control Release, 104(1): 51-66. [Abstract] [Full-text]
65. Biodegradable derivatives of tranexamic acid as transdermal permeation enhancers.
    J Control Release, 104(1): 41-9. [Abstract] [Full-text]
66. Successful treatment of photo-damaged skin of nano-scale atRA particles using a novel transdermal delivery.
    J Control Release, 104(1): 29-40. [Abstract] [Full-text]
67. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy.
    J Control Release, 104(1): 1-27. [Abstract] [Full-text]
68. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
    Lancet, 365(9470): 1543-51. [Abstract] [Full-text]
69. Early oral hydration and its impact on bowel activity after elective caesarean section--our experience.
    Eur J Obstet Gynecol Reprod Biol, 120(1): 53-6. [Abstract] [Full-text]
70. Impact of local guidelines and an integrated dispensing system on antibiotic prophylaxis quality in a surgical centre.
    J Hosp Infect, 60(2): 111-7. [Abstract] [Full-text]
71. Stress, appraisal, and coping: a comparison of HIV-infected women in the pre-HAART and HAART eras.
    J Psychosom Res, 58(3): 225-33. [Abstract] [Full-text]
72. Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes.
    Biochemistry, 44(18): 6948-57. [Abstract] [Full-text]
73. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
    J Pharm Sci, 94(6): 1343-53. [Abstract] [Full-text]
74. Nasal drug administration: potential for targeted central nervous system delivery.
    J Pharm Sci, 94(6): 1187-95. [Abstract] [Full-text]
75. Intra-arterial thrombolytic therapy in peri-coronary angiography ischemic stroke.
    Stroke, 36(5): 1089-90. [Abstract] [Full-text]
76. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.
    J Pediatr, 146(5): 654-61. [Abstract] [Full-text]
77. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
    Acta Haematol, 113(3): 155-62. [Abstract] [Full-text]
78. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    J Natl Cancer Inst, 97(9): 666-74. [Abstract] [Full-text]
79. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Urol Oncol, 23(2): 93-101. [Abstract] [Full-text]
80. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study.
    J Thromb Haemost, 3(5): 943-8. [Abstract] [Full-text]
81. Therapeutic neovascularization: contributions from bioengineering.
    Tissue Eng, 11(3): 567-84. [Abstract] [Full-text]
82. Sustained in vivo gene delivery from agarose hydrogel prolongs nonviral gene expression in skin.
    Tissue Eng, 11(3): 546-55. [Abstract] [Full-text]
83. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
    Br J Cancer, 92(9): 1655-62. [Abstract] [Full-text]
84. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
    Br J Cancer, 92(9): 1644-9. [Abstract] [Full-text]
85. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
    Br J Cancer, 92(9): 1650-4. [Abstract] [Full-text]
86. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
    Br J Cancer, 92(9): 1621-5. [Abstract] [Full-text]
87. A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia.
    Br J Cancer, 92(9): 1702-10. [Abstract] [Full-text]
88. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
    Br J Cancer, 92(9): 1636-43. [Abstract] [Full-text]
89. Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.
    Br J Cancer, 92(9): 1684-9. [Abstract] [Full-text]
90. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation.
    Bone Marrow Transplant, 35(10): 997-1001. [Abstract] [Full-text]
91. A trial of automated decision support alerts for contraindicated medications using computerized physician order entry.
    J Am Med Inform Assoc, 12(3): 269-74. [Abstract] [Full-text]
92. Fluorescence image-guided brain tumour resection with adjuvant metronomic photodynamic therapy: pre-clinical model and technology development.
    Photochem Photobiol Sci, 4(5): 438-42. [Abstract] [Full-text]
93. Estrogen replacement therapy increases plasma ghrelin levels.
    J Clin Endocrinol Metab, 90(5): 2954-63. [Abstract] [Full-text]
94. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis.
    J Vasc Interv Radiol, 16(5): 651-61. [Abstract] [Full-text]
95. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Cancer, 103(10): 2082-90. [Abstract] [Full-text]
96. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Cancer, 103(10): 2091-8. [Abstract] [Full-text]
97. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
    Cancer Chemother Pharmacol, 56(1): 75-82. [Abstract] [Full-text]
98. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Cancer, 103(10): 2109-17. [Abstract] [Full-text]
99. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
    Cancer Chemother Pharmacol, 56(1): 91-6. [Abstract] [Full-text]
100. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
     Cancer Chemother Pharmacol, 56(1): 10-4. [Abstract] [Full-text]
101. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
     J Clin Endocrinol Metab, 90(5): 2762-7. [Abstract] [Full-text]
102. Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement.
     J Clin Endocrinol Metab, 90(5): 2659-65. [Abstract] [Full-text]
103. Effect of leptin replacement on brain structure in genetically leptin-deficient adults.
     J Clin Endocrinol Metab, 90(5): 2851-4. [Abstract] [Full-text]
104. Sclerosing injections to areas of neo-vascularisation reduce pain in chronic Achilles tendinopathy: a double-blind randomised controlled trial.
     Knee Surg Sports Traumatol Arthrosc, 13(4): 338-44. [Abstract] [Full-text]
105. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial.
     J Clin Endocrinol Metab, 90(5): 2701-7. [Abstract] [Full-text]
106. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.
     Metabolism, 54(5): 561-7. [Abstract] [Full-text]
107. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy?
     J Steroid Biochem Mol Biol, 94(5): 499-518. [Abstract] [Full-text]
108. Bone-targeting macromolecular therapeutics.
     Adv Drug Deliv Rev, 57(7): 1049-76. [Abstract] [Full-text]
109. Designing proteins for bone targeting.
     Adv Drug Deliv Rev, 57(7): 1011-36. [Abstract] [Full-text]
110. Quest for the Holy Grail to cure arthritis and osteoporosis: emphasis on bone drug delivery systems.
     Adv Drug Deliv Rev, 57(7): 939-44. [Abstract] [Full-text]
111. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
     Eur J Endocrinol, 152(5): 719-26. [Abstract] [Full-text]
112. Reliability of CD4 quantitation in human immunodeficiency virus-positive children: implications for definition of immunologic response to highly active antiretroviral therapy.
     Clin Diagn Lab Immunol, 12(5): 640-3. [Abstract] [Full-text]
113. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
     Oral Oncol, 41(5): 526-33. [Abstract] [Full-text]
114. Vascular PET prostheses surface modification with cyclodextrin coating: development of a new drug delivery system.
     Eur J Vasc Endovasc Surg, 29(6): 628-32. [Abstract] [Full-text]
115. Testim 1% testosterone gel for the treatment of male hypogonadism.
     Clin Ther, 27(3): 286-98. [Abstract] [Full-text]
116. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting.
     Biomaterials, 26(28): 5727-36. [Abstract] [Full-text]
117. The effect of the antimicrobial peptide, Dhvar-5, on gentamicin release from a polymethyl methacrylate bone cement.
     Biomaterials, 26(28): 5717-26. [Abstract] [Full-text]
118. Real time computation of in vivo drug levels during drug self-administration experiments.
     Brain Res Brain Res Protoc, 15(1): 38-45. [Abstract] [Full-text]
119. Photodynamic therapy for periodontal diseases: state of the art.
     J Photochem Photobiol B, 79(2): 159-70. [Abstract] [Full-text]
120. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
     Ophthalmology, 112(5): 863-8. [Abstract] [Full-text]
121. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.
     Ophthalmology, 112(5): 771-9. [Abstract] [Full-text]
122. Volumetric preload measurement by thermodilution: a comparison with transoesophageal echocardiography.
     Br J Anaesth, 94(6): 748-55. [Abstract] [Full-text]
123. Early phase combined therapeutic management of acute ischaemic stroke.
     Neurol Sci, 26: S29-30. [Abstract] [Full-text]
124. Specific therapies for ischaemic stroke: rTPA and others.
     Neurol Sci, 26: S26-8. [Abstract] [Full-text]
125. Trends in exploration of therapeutic targets.
     Drug News Perspect, 18(2): 109-27. [Abstract] [Full-text]
126. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
     CMAJ, 172(10): 1307-12. [Abstract] [Full-text]
127. Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma.
     Auris Nasus Larynx, 32(1): 43-8. [Abstract] [Full-text]
128. The influence of growth hormone therapy on ultrasound myocardial tissue characterization in patients with childhood onset GH deficiency.
     Int J Cardiol, 101(2): 257-63. [Abstract] [Full-text]
129. Age- and sex-related utilisation of cardiac procedures and interventions: a multicentric study in Italy.
     Int J Cardiol, 101(2): 179-84. [Abstract] [Full-text]
130. Nondipping status does not attenuate the conjugated estrogen-induced improvement in aortic stiffness in postmenopausal women with untreated hypertension.
     Am J Hypertens, 18(5): 607-11. [Abstract] [Full-text]
131. Polypharmacy and Crohn's disease.
     Aliment Pharmacol Ther, 21(10): 1211-6. [Abstract] [Full-text]
132. Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and with tumor diameter greater than 4 cm.
     Int J Gynecol Cancer, 15(3): 483-8. [Abstract] [Full-text]
133. Clear-cell cancer of the ovary-is it chemosensitive?
     Int J Gynecol Cancer, 15(3): 432-7. [Abstract] [Full-text]
134. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube.
     Int J Gynecol Cancer, 15(3): 426-31. [Abstract] [Full-text]
135. Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?
     Int J Gynecol Cancer, 15(3): 420-5. [Abstract] [Full-text]
136. Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach.
     Otolaryngol Head Neck Surg, 132(5): 788-93. [Abstract] [Full-text]
137. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort.
     JAMA, 293(18): 2221-31. [Abstract] [Full-text]
138. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice.
     JAMA, 293(18): 2213-20. [Abstract] [Full-text]
139. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
     J Clin Oncol, 23(14): 3288-93. [Abstract] [Full-text]
140. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
     J Clin Oncol, 23(14): 3270-8. [Abstract] [Full-text]
141. Multiparameter evaluation of human thymic function: interpretations and caveats.
     Clin Immunol, 115(2): 138-46. [Abstract] [Full-text]
142. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
     Urol Oncol, 23(1): 1-7. [Abstract] [Full-text]
143. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
     Urology, 65(5): 3-7; discussion 7-8. [Abstract] [Full-text]
144. 5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma.
     Exp Dermatol, 14(6): 429-37. [Abstract] [Full-text]
145. Doppler ultrasound and clinical findings in patients with acute ischemic stroke treated with intravenous thrombolysis.
     Eur J Neurol, 12(6): 462-5. [Abstract] [Full-text]
146. Treatment of advanced malignant eccrine poroma with locoregional chemotherapy.
     Br J Dermatol, 152(5): 1051-5. [Abstract] [Full-text]
147. Phototherapy and photochemotherapy of sclerosing skin diseases.
     Photodermatol Photoimmunol Photomed, 21(3): 157-65. [Abstract] [Full-text]
148. The course of anticoagulation after extracorporeal photochemotherapy.
     Photodermatol Photoimmunol Photomed, 21(3): 150-1. [Abstract] [Full-text]
149. Photodynamic therapy in dermatology--an update.
     Photodermatol Photoimmunol Photomed, 21(3): 142-9. [Abstract] [Full-text]
150. Renal function during and after treatment for acute lymphoblastic leukemia in children.
     Pediatr Nephrol, 20(6): 782-5. [Abstract] [Full-text]
151. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
     Int J Radiat Oncol Biol Phys, 62(2): 508-13. [Abstract] [Full-text]
152. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
     Int J Radiat Oncol Biol Phys, 62(2): 342-50. [Abstract] [Full-text]
153. Chemotherapy in the primary treatment of cervical carcinoma.
     Crit Rev Oncol Hematol, 54(3): 197-208. [Abstract] [Full-text]
154. Colonic rupture in a patient on combination chemotherapy for metastasized carcinoma of the esophagogastric junction. Case report and review of the literature.
     Onkologie, 28(4): 204-6. [Abstract] [Full-text]
155. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
     Lancet, 365(9472): 1687-717. [Abstract] [Full-text]
156. Duration of an intermittent episode of viremia.
     Bull Math Biol, 67(4): 885-900. [Abstract] [Full-text]
157. A decrease in drug resistance levels of the HIV epidemic can be bad news.
     Bull Math Biol, 67(4): 761-82. [Abstract] [Full-text]
158. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.
     Biochim Biophys Acta, 1669(2): 155-63. [Abstract] [Full-text]
159. Prevention of prescription errors by computerized, on-line surveillance of drug order entry.
     Int J Med Inform, 74(5): 377-86. [Abstract] [Full-text]
160. Collecting information on the quality of prescribing in primary care using semi-automatic data extraction from GPs' electronic medical records.
     Int J Med Inform, 74(5): 367-76. [Abstract] [Full-text]
161. Factors affecting protein release from microcapsule prepared by liposome in alginate.
     Colloids Surf B Biointerfaces, 42(3): 253-8. [Abstract] [Full-text]
162. The dynamic range of biologic functions and variation of many environmental cues may be declining in the modern age: implications for diseases and therapeutics.
     Med Hypotheses, 65(1): 173-8. [Abstract] [Full-text]
163. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
     Lung Cancer, 48(3): 429-34. [Abstract] [Full-text]
164. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC).
     Lung Cancer, 48(3): 415-22. [Abstract] [Full-text]
165. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
     Lung Cancer, 48(3): 409-13. [Abstract] [Full-text]
166. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
     Lung Cancer, 48(3): 389-97. [Abstract] [Full-text]
167. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
     Lung Cancer, 48(3): 379-87. [Abstract] [Full-text]
168. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy.
     BJU Int, 95(9): 1237-44. [Abstract] [Full-text]
169. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
     BJU Int, 95(9): 1206-10. [Abstract] [Full-text]
170. Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
     Intern Med J, 35(6): 336-42. [Abstract] [Full-text]
171. Mechanistic studies on aggregation of polyethylenimine-DNA complexes and its prevention.
     Biotechnol Bioeng, 90(5): 614-20. [Abstract] [Full-text]
172. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000.
     J Infect Dis, 191(12): 2038-45. [Abstract] [Full-text]
173. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
     Clin Cancer Res, 11(10): 3854-61. [Abstract] [Full-text]
174. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
     Clin Cancer Res, 11(10): 3836-45. [Abstract] [Full-text]
175. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
     Mol Cancer Ther, 4(5): 843-54. [Abstract] [Full-text]
176. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
     Mol Cancer Ther, 4(5): 824-34. [Abstract] [Full-text]
177. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
     J Dermatolog Treat, 16(1): 19-21. [Abstract] [Full-text]
178. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
     Eur J Cardiothorac Surg, 27(6): 1092-8. [Abstract] [Full-text]
179. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
     Eur J Cardiothorac Surg, 27(6): 1086-91. [Abstract] [Full-text]
180. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina.
     Eur J Cardiothorac Surg, 27(6): 1051-6. [Abstract] [Full-text]
181. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
     Biochem Pharmacol, 69(11): 1585-94. [Abstract] [Full-text]
182. Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records.
     J Clin Pharm Ther, 30(3): 259-69. [Abstract] [Full-text]
183. Advice-giving on self-medication: perspectives of community pharmacists and consumers in Singapore.
     J Clin Pharm Ther, 30(3): 225-31. [Abstract] [Full-text]
184. User-related pharmaceutical care problems and factors affecting them: the importance of clinical relevance.
     J Clin Pharm Ther, 30(3): 215-23. [Abstract] [Full-text]
185. Patient valuation of pharmacist services for self care with OTC medications.
     J Clin Pharm Ther, 30(3): 193-9. [Abstract] [Full-text]
186. Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's health initiative.
     Endocr Rev, 26(3): 308-12. [Abstract] [Full-text]
187. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
     Clin Pharmacol Ther, 77(5): 404-14. [Abstract] [Full-text]
188. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
     JAMA, 293(19): 2367-71. [Abstract] [Full-text]
189. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel.
     Cancer Res, 65(10): 4401-7. [Abstract] [Full-text]
190. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
     Cancer Res, 65(10): 4300-8. [Abstract] [Full-text]
191. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
     Cancer Res, 65(10): 4181-90. [Abstract] [Full-text]
192. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs.
     Soc Sci Med, 61(3): 565-76. [Abstract] [Full-text]
193. Allergic contact dermatitis from ophthalmic products: can pre-treatment with sodium lauryl sulfate increase patch test sensitivity?
     Contact Dermatitis, 52(5): 239-41. [Abstract] [Full-text]
194. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
     Br J Cancer, 92(10): 1846-9. [Abstract] [Full-text]
195. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
     Br J Cancer, 92(10): 1850-4. [Abstract] [Full-text]
196. Cardiovascular pharmacogenomics.
     Exp Physiol, 90(3): 283-9. [Abstract] [Full-text]
197. Does gene therapy become pharmacotherapy?
     Exp Physiol, 90(3): 307-13. [Abstract] [Full-text]
198. Visual feedback therapy to enhance medication adherence in psychosis.
     Arch Psychiatr Nurs, 19(2): 70-80. [Abstract] [Full-text]
199. Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy.
     Pharmacopsychiatry, 38(3): 128-31. [Abstract] [Full-text]
200. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
     Am J Obstet Gynecol, 192(5): 1365-7. [Abstract] [Full-text]
201. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro.
     Phys Med Biol, 50(11): 2597-616. [Abstract] [Full-text]
202. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection.
     Am J Epidemiol, 161(11): 999-1012. [Abstract] [Full-text]
203. The use of hypromellose in oral drug delivery.
     J Pharm Pharmacol, 57(5): 533-46. [Abstract] [Full-text]
204. Perioperative adjunctive treatment in the management of operable gastric cancer.
     J Surg Oncol, 90(3): 174-86; discussion 186-7. [Abstract] [Full-text]
205. The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin.
     Hum Reprod, 20(6): 1741-5. [Abstract] [Full-text]
206. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.
     Eur Radiol, 15(6): 1224-33. [Abstract] [Full-text]
207. Intrusion and confusion--the impact of medication and health professionals after acute myocardial infarction.
     Eur J Cardiovasc Nurs, 4(2): 153-9. [Abstract] [Full-text]
208. Thrombolysis nurses: time for review.
     Eur J Cardiovasc Nurs, 4(2): 129-37. [Abstract] [Full-text]
209. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening.
     Dis Colon Rectum, 48(4): 799-808. [Abstract] [Full-text]
210. Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing.
     Nat Methods, 2(6): 449-54. [Abstract] [Full-text]
211. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
     J Clin Oncol, 23(15): 3562-7. [Abstract] [Full-text]
212. Patient online self-reporting of toxicity symptoms during chemotherapy.
     J Clin Oncol, 23(15): 3552-61. [Abstract] [Full-text]
213. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
     J Clin Oncol, 23(15): 3545-51. [Abstract] [Full-text]
214. Clinical value of mitochondrial mutations in colorectal cancer.
     J Clin Oncol, 23(15): 3517-25. [Abstract] [Full-text]
215. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
     J Clin Oncol, 23(15): 3509-16. [Abstract] [Full-text]
216. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
     J Clin Oncol, 23(15): 3502-8. [Abstract] [Full-text]
217. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
     J Clin Oncol, 23(15): 3488-94. [Abstract] [Full-text]
218. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
     J Clin Oncol, 23(15): 3480-7. [Abstract] [Full-text]
219. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
     J Clin Oncol, 23(15): 3383-9. [Abstract] [Full-text]
220. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
     J Clin Oncol, 23(15): 3331-42. [Abstract] [Full-text]
221. The engineering of membrane-permeable peptides.
     Anal Biochem, 341(2): 290-8. [Abstract] [Full-text]
222. Synthesis of a novel PEG-block-poly(aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier.
     Int J Pharm, 297(1): 242-53. [Abstract] [Full-text]
223. Controlled release from fibers of polyelectrolyte complexes.
     J Control Release, 104(2): 347-58. [Abstract] [Full-text]
224. Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery.
     J Control Release, 104(2): 259-70. [Abstract] [Full-text]
225. The Women's Health Initiative conundrum.
     Arch Women Ment Health, 8(1): 7-14. [Abstract] [Full-text]
226. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).
     Ann Oncol, 16(6): 915-22. [Abstract] [Full-text]
227. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.
     Int J Pharm, 297(1): 89-97. [Abstract] [Full-text]
228. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
     Ann Oncol, 16(6): 869-77. [Abstract] [Full-text]
229. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
     Ann Oncol, 16(6): 878-86. [Abstract] [Full-text]
230. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
     Ann Oncol, 16(6): 950-7. [Abstract] [Full-text]
231. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
     Ann Oncol, 16(6): 923-7. [Abstract] [Full-text]
232. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
     J Clin Oncol, 23(15): 3568-76. [Abstract] [Full-text]
233. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
     J Clin Oncol, 23(15): 3343-51. [Abstract] [Full-text]
234. What are the beliefs and attitudes of paramedics to prehospital thrombolysis? A questionnaire study.
     Emerg Med J, 22(6): 450-1. [Abstract] [Full-text]
235. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
     Arch Intern Med, 165(10): 1179-84. [Abstract] [Full-text]
236. Decisions on drug therapies by numbers needed to treat: a randomized trial.
     Arch Intern Med, 165(10): 1140-6. [Abstract] [Full-text]
237. Physician specialization and the quality of care for human immunodeficiency virus infection.
     Arch Intern Med, 165(10): 1133-9. [Abstract] [Full-text]
238. High rates of adverse drug events in a highly computerized hospital.
     Arch Intern Med, 165(10): 1111-6. [Abstract] [Full-text]
239. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
     J Clin Virol, 33(3): 206-16. [Abstract] [Full-text]
240. Synthesis of glycoporphyrin derivatives and their antiviral activity against herpes simplex virus types 1 and 2.
     Bioorg Med Chem, 13(12): 3878-88. [Abstract] [Full-text]
241. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
     Eur J Cancer, 41(8): 1213-22. [Abstract] [Full-text]
242. Photothermal sensitisation as a novel therapeutic approach for tumours: studies at the cellular and animal level.
     Eur J Cancer, 41(8): 1203-12. [Abstract] [Full-text]
243. Amino acid concentrations in cerebrospinal fluid in children with acute lymphoblastic leukemia undergoing chemotherapy.
     Eur J Cancer, 41(8): 1158-63. [Abstract] [Full-text]
244. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
     Eur J Cancer, 41(8): 1150-7. [Abstract] [Full-text]
245. Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method.
     Eur J Pharm Sci, 25(2): 307-12. [Abstract] [Full-text]
246. Targeting liposomes with protein drugs to the blood-brain barrier in vitro.
     Eur J Pharm Sci, 25(2): 299-305. [Abstract] [Full-text]
247. Polyelectrolyte complex formation and stability when mixing polyanions and polycations in salted media: a model study related to the case of body fluids.
     Eur J Pharm Sci, 25(2): 281-8. [Abstract] [Full-text]
248. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D,L-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid).
     J Control Release, 104(3): 477-88. [Abstract] [Full-text]
249. Aging and microwave effects on alginate/chitosan matrices.
     J Control Release, 104(3): 461-75. [Abstract] [Full-text]
250. Modification of the effects of estrogen therapy on HDL cholesterol levels by polymorphisms of the HDL-C receptor, SR-BI: the Rancho Bernardo Study.
     Atherosclerosis, 180(2): 255-62. [Abstract] [Full-text]
251. Deferoxamine photosensitizes cancer cells in vitro.
     Biochem Biophys Res Commun, 332(2): 388-91. [Abstract] [Full-text]
252. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
     Fundam Clin Pharmacol, 19(3): 373-83. [Abstract] [Full-text]
253. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint.
     Pediatr Transplant, 9(3): 398-407. [Abstract] [Full-text]
254. Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid.
     Photomed Laser Surg, 23(2): 206-11. [Abstract] [Full-text]
255. Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts.
     Photomed Laser Surg, 23(2): 202-5. [Abstract] [Full-text]
256. Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model.
     Photomed Laser Surg, 23(2): 172-6. [Abstract] [Full-text]
257. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
     Biochem Biophys Res Commun, 332(2): 433-40. [Abstract] [Full-text]
258. A role for manganese superoxide dismutase in apoptosis after photosensitization.
     Biochem Biophys Res Commun, 332(2): 411-7. [Abstract] [Full-text]
259. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
     Cancer, 103(11): 2298-303. [Abstract] [Full-text]
260. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.
     Cancer, 103(11): 2349-54. [Abstract] [Full-text]
261. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
     Leukemia, 19(6): 978-83. [Abstract] [Full-text]
262. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
     Cancer, 103(11): 2252-60. [Abstract] [Full-text]
263. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
     Leukemia, 19(6): 984-9. [Abstract] [Full-text]
264. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
     Cancer, 103(11): 2338-43. [Abstract] [Full-text]
265. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
     Leukemia, 19(6): 945-52. [Abstract] [Full-text]
266. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
     Ann Surg Oncol, 12(5): 398-405. [Abstract] [Full-text]
267. Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization.
     Invest Ophthalmol Vis Sci, 46(6): 2168-74. [Abstract] [Full-text]
268. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group.
     Int J Hematol, 81(4): 342-8. [Abstract] [Full-text]
269. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
     Int J Hematol, 81(4): 319-22. [Abstract] [Full-text]
270. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
     J Immunol Methods, 299(1): 63-76. [Abstract] [Full-text]
271. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
     J Surg Oncol, 90(4): 220-5. [Abstract] [Full-text]
272. Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.
     J Surg Oncol, 90(4): 209-19. [Abstract] [Full-text]
273. Intraarterial thrombolysis and stent placement in the acute phase of blunt internal carotid artery trauma with subocclusive dissection and thromboembolic complication: case report and review of the literature.
     Ann Vasc Surg, 19(3): 434-7. [Abstract] [Full-text]
274. Compartment syndrome after compression sclerotherapy.
     Ann Vasc Surg, 19(3): 428-30. [Abstract] [Full-text]
275. Multistage ethanol sclerotherapy of soft-tissue arteriovenous malformations: effect on pulmonary arterial pressure.
     Radiology, 235(3): 1072-7. [Abstract] [Full-text]
276. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
     J Clin Pathol, 58(6): 650-4. [Abstract] [Full-text]
277. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy.
     Free Radic Biol Med, 38(12): 1565-70. [Abstract] [Full-text]
278. Packaging the replicon RNA of the Far-Eastern subtype of tick-borne encephalitis virus into single-round infectious particles: development of a heterologous gene delivery system.
     Vaccine, 23(30): 3946-56. [Abstract] [Full-text]
279. Selective sparing of brain tissue in postmenopausal women receiving hormone replacement therapy.
     Neurobiol Aging, 26(8): 1205-13. [Abstract] [Full-text]
280. Evidence on antibiotic prophylaxis for cesarean section alone is not sufficient to change the practices of doctors in a teaching hospital.
     J Obstet Gynaecol Res, 31(3): 202-9. [Abstract] [Full-text]
281. Patients' answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectional survey.
     AIDS Patient Care STDS, 19(5): 317-25. [Abstract] [Full-text]
282. Evaluation of an antiretroviral medication attitude scale and relationships between medication attitudes and medication nonadherence.
     AIDS Patient Care STDS, 19(5): 306-16. [Abstract] [Full-text]
283. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
     J Med Chem, 48(11): 3729-35. [Abstract] [Full-text]